Cargando…
Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia—Preliminary results from a randomized controlled trial
OBJECTIVES: There is great interest in developing and studying novel therapies for epistaxis in hereditary hemorrhagic telangiectasia (HHT) given its associated morbidity and impact on patients' quality of life. Several recent randomized controlled trials (RCTs) have been negative, likely attri...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223446/ https://www.ncbi.nlm.nih.gov/pubmed/34195356 http://dx.doi.org/10.1002/lio2.561 |